About Cellarcus Biosciences
Cellarcus Biosciences is a company based in San Diego (United States) founded in 2017. Cellarcus Biosciences offers products and services including vFC™ Vesicle Analysis Assays, vTag™ Antibodies, Vesicles and Vesicle Assay Standards, and evCRO Vesicle Analysis Services. Cellarcus Biosciences operates in a competitive market with competitors including Alamar Biosciences, Glympse Bio, Harmonic Discovery, Seahorse Bioscience and Luceome Biotechnologies, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Cellarcus Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$2 M (USD), Grant
Jun 09, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellarcus Biosciences
Cellarcus Biosciences offers a comprehensive portfolio of products and services, including vFC™ Vesicle Analysis Assays, vTag™ Antibodies, Vesicles and Vesicle Assay Standards, and evCRO Vesicle Analysis Services.
Assays for direct EV measurement in biofluids.
Antibodies for no-wash EV cargo quantitation.
Standards for accurate EV sizing and calibration.
Services for professional EV analysis support.
Funding Insights of Cellarcus Biosciences
Investors in Cellarcus Biosciences
Cellarcus Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Cellarcus Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellarcus Biosciences
Investment portfolio details for Cellarcus Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellarcus Biosciences
Detailed financials for Cellarcus Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellarcus Biosciences Comparisons
Peer comparison for Cellarcus Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellarcus Biosciences
Cellarcus Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alamar Biosciences, Glympse Bio, Harmonic Discovery, Seahorse Bioscience and Luceome Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ultra-high sensitivity protein analysis solutions are provided across multiplex levels.
|
|
| Locked | Locked | Locked |
Multiple human diseases are monitored noninvasively through urine-based analysis.
|
|
| Locked | Locked | Locked |
Developer of kinase inhibitor drugs for oncology
|
|
| Locked | Locked | Locked |
Cellular metabolic status is measured via the Seahorse XFp Analyzer.
|
|
| Locked | Locked | Locked |
Assay technology is developed for identifying drugs against kinases.
|
|
| Locked | Locked | Locked |
Develops innovative in-vitro diagnostic platforms using optical interrogation of biochip-kits.
|
Detailed competitors of Cellarcus Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellarcus Biosciences
Complete news archive for Cellarcus Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellarcus Biosciences
Cellarcus Biosciences was founded in 2017.
Cellarcus Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
John Nolan is the current CEO of Cellarcus Biosciences.
Cellarcus Biosciences was founded in 2017 and is based in San Diego, United States. Operations are conducted in the biotechnology sector, where analysis of extracellular vesicles is performed in biofluids, culture supernatant, and isolated samples. The vFC assay is utilized for counting and sizing vesicles in media or buffers. Services target research and diagnostic applications in life sciences.
Cellarcus Biosciences's top competitors include Alamar Biosciences, Glympse Bio and Harmonic Discovery.
Cellarcus Biosciences offers vFC™ Vesicle Analysis Assays, vTag™ Antibodies, Vesicles and Vesicle Assay Standards, and evCRO Vesicle Analysis Services.
Cellarcus Biosciences has 1 investor. Key investors include HHS.